MEREO BIOPHARMA GROUP PLC Shares Outstanding (Cover Page)
MEREO BIOPHARMA GROUP PLC (MREO) had Shares Outstanding (Cover Page) of 798.45 million shares as of 2026-08-07, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Cover Page
dei:EntityCommonStockSharesOutstanding · last filed 2026-08-11
- 2026-08-07: Entity Common Stock, Shares Outstanding 798.45M shares.
- 2026-05-11: Entity Common Stock, Shares Outstanding 798.09M shares.
- 2026-03-18: Entity Common Stock, Shares Outstanding 798.08M shares.
- 2025-11-10: Entity Common Stock, Shares Outstanding 795.66M shares.
| Period end | Entity Common Stock, Shares Outstanding |
|---|---|
| 2026-08-07 | 798.45M shares 10-Q · filed 2026-08-11 |
| 2026-05-11 | 798.09M shares 10-Q · filed 2026-05-12 |
| 2026-03-18 | 798.08M shares 10-K · filed 2026-03-19 |
| 2025-11-10 | 795.66M shares 10-Q · filed 2025-11-10 |
| 2025-08-11 | 795.48M shares 10-Q · filed 2025-08-12 |
| 2025-05-12 | 795.00M shares 10-Q · filed 2025-05-13 |
| 2025-03-25 | 795.00M shares 10-K · filed 2025-03-26 |
| 2024-11-11 | 775.73M shares 10-Q · filed 2024-11-12 |
| 2024-08-12 | 769.26M shares 10-Q · filed 2024-08-13 |
| 2024-05-15 | 701.36M shares 10-Q · filed 2024-05-15 |
| 2024-02-29 | 701.29M shares 10-K · filed 2024-03-27 |
| 2022-12-31 | 624.93M shares 20-F · filed 2023-03-28 |
| 2021-12-31 | 584.91M shares 20-F · filed 2022-03-31 |
| 2020-12-31 | 338.95M shares 20-F · filed 2021-03-31 |
| 2019-12-31 | 97.96M shares 20-F · filed 2020-06-15 |
| 2018-12-31 | 71.24M shares 20-F/A · filed 2019-05-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |